Patient Experience with ABBV-444, a Proof-of-Concept Study for a Novel Artificial Tear with Trehalose and Sodium Hyaluronate for Dry Eye Symptoms
Continuous daily treatment with ABBV-444 reduced DED symptom severity over 30 days and demonstrated rapid onset of action within 30 seconds post administration. These results suggest that ABBV-444 is a viable therapy for DED symptoms and support further investigation of longer-term treatment in multicenter trials.
Authors
- Sadhana Sonparote
- Zuoyi Zhang (ORCID: https://orcid.org/0000-0002-9039-5418)
- Milton M. Hom (ORCID: https://orcid.org/0000-0001-9683-6520)
- Haixia Liu (ORCID: https://orcid.org/0000-0003-1047-3023)
- Omar Ladhani
- Charlotte Dancey
Institutions
- AbbVie (United States) (US)
- Eye Care Associates (US)
Publication Details
- Journal
- Clinical Optometry
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/opto.s490732
- Citations
- 1
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Allergan